Tolerance, Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 09 Aug 2023
At a glance
- Drugs QLH-12016 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 09 Aug 2023 New trial record